Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.

Data from a 101-patient ‌study showed that ⁠52.5% ⁠of those previously treated with Pluvicto saw levels of prostate-specific antigen, or PSA, fall by at least half when treated ​with the actinium-based drug. Elevated PSA level is a common marker for prostate cancer.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.